from Business Spectator
Biota Holdings, Nabi Pharmaceuticals
Nothing comes easy for Biota Holdings.
The small biotech company is trying to orchestrate a backdoor listing on the Nasdaq via a reverse takeover of US-listed Nabi Pharmaceuticals, which is basically a cash box.
It’s not an ideal situation for shareholders to be left with US scrip, but it’s what Biota feels is necessary if it’s access America’s enormously larger market.
The company’s share slid 4 per cent yesterday after Biota announced a new merger structure that would leave shareholders with a larger stake in the new company, which will be carrying less cash than expected.
Nabi shareholders will now collect between $US28 million and $US31 million in cash, which will leave $US27 million left over for the US-listed Biota Pharmaceuticals.
Biota shareholders will receive 81.5 per cent to 85.8 per cent of the company, up from 74 per ce
- Forums
- ASX - By Stock
- BTA
- nabi pricing interesting now
nabi pricing interesting now, page-7
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online